Cited 12 times in
Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임선민 | - |
dc.date.accessioned | 2022-11-24T00:42:22Z | - |
dc.date.available | 2022-11-24T00:42:22Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190920 | - |
dc.description.abstract | Antibiotic-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors. We investigated the impact of antibiotics on the clinical outcomes of nivolumab in patients with non-small cell lung cancer (NSCLC). Patients who received nivolumab for NSCLC between July 2015 and June 2018 and who were followed up until June 2020 were included in a retrospective cohort analysis. Of 140 eligible patients, 70 were on antibiotics. Overall survival (OS) was shorter in patients on antibiotics (ABX) compared to those not on antibiotics (NoABX) (p = 0.014). OS was negatively associated with piperacillin/tazobactam (PTZ) (HR = 3.31, 95% CI: 1.77-6.18), days of therapy (DOT) ≥ 2 weeks (HR = 2.56, 95% CI: 1.30-5.22) and DOT of PTZ. The defined daily dose (DDD) in PTZ (r = 0.27) and glycopeptides (r = 0.21) showed weak correlations with mortality. There was no difference in progression-free survival (PFS) between ABX and NoABX; however, PFS was negatively associated with the antibiotic class PTZ and DOT of PTZ. Therefore, the use of a broad-spectrum antibiotic, such as PTZ, the long-term use of antibiotics more than 2 weeks in total and the large amount of defined daily dose of specific antibiotics were associated with decreased survival in patients receiving nivolumab for NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Min Jung Geum | - |
dc.contributor.googleauthor | Chungsoo Kim | - |
dc.contributor.googleauthor | Ji Eun Kang | - |
dc.contributor.googleauthor | Jae Hee Choi | - |
dc.contributor.googleauthor | Jae Song Kim | - |
dc.contributor.googleauthor | Eun Sun Son | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Sandy Jeong Rhie | - |
dc.identifier.doi | 10.3390/ph14050445 | - |
dc.contributor.localId | A03369 | - |
dc.relation.journalcode | J04088 | - |
dc.identifier.pmid | 34066877 | - |
dc.subject.keyword | antibiotic-induced dysbiosis | - |
dc.subject.keyword | days of therapy | - |
dc.subject.keyword | defined daily dose | - |
dc.subject.keyword | nivolumab | - |
dc.subject.keyword | non-small cell lung cancer | - |
dc.subject.keyword | overall survival | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | 임선민 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 445 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICALS, Vol.14(5) : 445, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.